ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous investigation and successful validation of 150 test samples. The company’s innovative technology utilizes active salivary biomarkers to detect early signs of oral cancer, demonstrating a sensitivity of 98% and a specificity of 100%. The trials will further explore the effectiveness of ErlySign’s automated multi-sample reader that processes tests within 15-20 minutes, enhancing testing efficiency. This approval marks a significant advancement in cancer diagnostics, paving the way for a new era in preventive health care.
